A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

Study summary

The goal of this research agenda is to improve the quality of end-of-life care by explicitly identifying values that will guide the decision-making process, with a particular emphasis on the role of ethnic, racial and cultural factors.

Ask AI to explain this study

Start here

Key things to know

Main goalHealth Services Research

This describes the study’s primary purpose.

What is being studiedValues Inventory (VI)

The study team can explain what participation involves.

Who it may be forCongestive Heart Failure · Chronic Obstructive Pulmonary Disease

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 14, 2015 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?VA Office of Research and Development

Study sponsor

Study overview

What this study is about

Purpose: Health Services Research
Study type: Interventional
Phase: Not applicable
Sponsor: VA Office of Research and Development
Interventions being studied: Other: Values Inventory (VI)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Eligible patients will be at risk for 6-12 month mortality and have one of the following diagnoses:
congestive heart failure, with ejection fraction of \<25%;
severe chronic obstructive pulmonary disease/emphysema with dependence on oxygen;
chronic liver disease with cirrhosis and ascites;
colon carcinoma with liver metastases; or
non-small cell cancer of the lung, stage III or IV
chronic kidney disease on renal replacement therapy, with previous hospitalization
All participants will be age 55 years or older and will be recruited through the clinics at the Houston VAMC.

Reasons someone may not be able to joinExclusion criteria

Patients with dementia
Patients less than 55 years old

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Michael E DeBakey VA Medical CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 14, 2015. Always confirm current availability with the study team.

View original record ↗